deCODE Receives Trading Suspension and Delisting Notice from Nasdaq
News Jan 05, 2010
deCODE genetics, Inc. has announced that it has received notice from the Nasdaq Stock Market that the company’s common stock will be suspended from the Nasdaq Stock Market as of the open of business on January 6, 2010 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove deCODE’s common stock from listing on Nasdaq.
Following this action, it is possible that deCODE’s common stock will be traded on the inter-dealer quotation service known as the “Pink Sheets.” However this is not certain, as it would require a market maker to quote the stock, and there is no guarantee that any market maker will do so.
In addition, so long as deCODE is not current in its reporting obligations under the Securities Exchange Act of 1934, any such quotation will be subject to additional restrictions.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE